

May 8, 2002

Dockets Management Branch
Food and Drug Administration
Department of Health and Human Services
12420 Parklawn Dr. Room 1-23
Rockville, MD 20857

VIA FEDERAL EXPRESS

Dear Food and Drug Administration:

Citizen Petition

The undersigned submits this petition under 21 CFR §10.25 to request that the Commissioner of Food and Drugs amend the publication "Approved Drug Products with Therapeutic Equivalence Evaluations" (Orange Book) for Fluocinonide Emulsified Base. Altana requests that Lidex-E® NDA 16-908-003 also be designated as the Reference Listed Drug for this product.

A. Action requested

The 22nd edition of the Orange Book designates both Lidex® and Lidex-E®, approved under NDA 16-908-002 and 16-908-003, respectively, as AB. Altana Inc. requests that Lidex-E® be designated as AB1 as the two drug products have been demonstrated to be bio-inequivalent.

B. Statement of grounds

Altana Inc. conducted a one-period, randomized, vasoconstrictor assay to compare the effects of two topical fluocinonide 0.05% creams (Lidex® and Lidex-E®). For the purpose of this study, Lidex-E® was considered the test product and Lidex® the Reference. Results obtained from this study yielded a test-to-reference ratio of 75.1 with a 90% confidence interval of 67.2 - 83.1%. This data does not meet the current limits of 80 - 120% for determining the bioequivalence of two topical corticosteroids.

In accordance with 21 CFR §10.20(a) and (c), four copies of the bioequivalence study and data diskette have been provided as **Attachment I**.

C. Environmental impact

Altana Inc. claims a categorical exclusion under 21 CFR §25.30 (h). In accordance with the provisions established in 21 CFR §25.23 and §25.24, the action that is the subject of this petition is excluded from the requirement to prepare an Environmental Assessment because the actions meet specific requirements that are intended to ensure that they will not cause significant environmental effects.

02P-0219

CP 1

D. Certification

The undersigned certifies, that, to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioner which are unfavorable to the petition.

All regulatory correspondence related to this Citizen Petition should be addressed to the following individual:

Ms. Audrey Bialeski
Manager, Regulatory Affairs
Altana, Inc.
60 Baylis Road
Melville, NY 11747
Telephone: (631) 454-7677, extension 3007
Facsimile: (631) 756-5114

Sincerely,
ALTANA INC.

for

Robert J. Anderson, Esq.
Senior Director, Scientific Affairs
60 Baylis Road
Melville, NY 11747
Telephone: (631) 454-7677, extension 2085
Facsimile: (631) 756-5114

RJA:jfa

ALTANA

Altana Inc. 60 Baylis Road, Melville, N.Y. 11747 631-454-7677

May 9, 2002

Dockets Management Branch
Food and Drug Administration
Department of Health and Human Services
5630 Fishers Lane Room 1061
Rockville, MD 20852
Tel: 301-827-6869
Fax: 301-827-6870

VIA FACSIMILE

035 '02 MAY -9 P1 109


**Amendment
Citizen Petition**

Dear Food and Drug Administration:

Further to the discussion on May 9, 2002 between FDA representatives and Altana personnel, Altana Inc. agrees that information contained in the submitted Citizen Petition can be included as part of the Public Docket. Please consider this correspondence as Altana's release for the confidential protocol included as part of the clinical study report.

If you have any questions or require additional information, please contact Ms. Audrey Bialeski at (631) 454-7677 extension 3007. FAX communications can be made to (631) 756-5114.

Sincerely,
ALTANA INC.



Robert J. Anderson, Esq.
Senior Director, Scientific Affairs

RJA:jfa

TELEFAX DATED: May 9, 2002

ALTANA

Altana Inc. 60 Baylis Road, Melville, NY 11747 631-454-7677 Fax: 631-756-5114

BYK GULDEN PHARMA GROUP

TO: Mr. Lyle Jaffe

FAX NO: 301-827-6870

FROM: Mr. Robert J. Anderson, Esq.

OF PAGES (including this page): 2

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the addressee, or person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us at the above address by mail. Thank you.

**Amendment
Citizen Petition**

Dear Mr. Jaffe:

Reference is made to the conference call on Thursday, May 9, 2002, between FDA representatives and Altana personnel. As discussed, enclosed please find a Facsimile Amendment to the Altana Inc. Citizen Petition file dated May 8, 2002.

If you have any questions or require additional information, please contact Ms. Audrey Bialeski at (631) 454-7677 extension 3007. FAX communications can be made to (631) 756-5114.

Sincerely,
ALTANA INC.

Robert J. Anderson, Esq.
Senior Director, Scientific Affairs

RJA:jfa



**A ONE PERIOD, RANDOMIZED, VASOCONSTRICTOR
ASSAY STUDY TO COMPARE THE RELATIVE
VASOCONSTRICTIVE EFFECTS OF TWO TOPICAL
FLUOCINONIDE 0.05% CREAMS**

STUDY NO. 10228207

DRUG: Fluocinonide, 0.05%

PROTOCOL NO: 10228207, Revision 1 (02/04/02)

DESIGN: One-Period, Randomized,
Vasoconstrictor Study

TEST: Lidex-E[®] (fluocinonide) Cream, 0.05%
Manufactured for MEDICIS, The Dermatology
Company[®] by Patheon, Inc.
Lot No. RAD028, Expiration date 02/03

REFERENCE: Lidex[®] (fluocinonide) Cream, 0.05%
Manufactured for MEDICIS, The Dermatology
Company[®] by Patheon, Inc.
Lot No. RAB040, Expiration date 02/04

SPONSOR: Altana, Inc.
Melville, NY

PREPARED BY: Novum Pharmaceutical Research Services
Pittsburgh, PA

VOLUME: 1 of 2



**A ONE PERIOD, RANDOMIZED, VASOCONSTRICTOR
ASSAY STUDY TO COMPARE THE RELATIVE
VASOCONSTRICTIVE EFFECTS OF TWO TOPICAL
FLUOCINONIDE 0.05% CREAMS**

STUDY NO. 10228207

We authorize release of the final study report for this study
which was performed in accordance with
Protocol No. 10228207, Revision 1 (02/04/02).

A handwritten signature in black ink, appearing to read "CH Hendy", written over a horizontal line.

Christopher H. Hendy, Ph.D.
President and CEO
Novum Pharmaceutical Research Services

3/21/02

Date

A handwritten signature in black ink, appearing to read "Valerie Balavage", written over a horizontal line.

Valerie Balavage
Biostatistician
Novum Pharmaceutical Research Services

3/26/02

Date



QUALITY ASSURANCE STATEMENT

Sponsor: Altana, Inc.
Drugs: Lidex[®] E (fluocinonide) Cream 0.05% and
Lidex[®] (fluocinonide) Cream 0.05%
Study Title: A One Period, Randomized, Vasoconstrictor Assay Study To Compare
the Relative Vasoconstrictive Effects of Two Topical Fluocinonide
0.05% Creams
Study Number: 10228207
Protocol Number: 10228207 (Revision 1)

CLINICAL OPERATIONS:

The following clinical operations were observed during study conduct:

Group 1: Dosing and Removal Procedures

REPORT:

The following text, tables, schedules and statistical data were reviewed for accurate representation within this report:

CLINICAL SUMMARY

Summary (Section 1)

Table C1: Subject Characteristics

Table C2: Schedule of Treatments and Actual Application and Removal Times

Table C3: Summary of Adverse Events

Activity Schedule

Meals and Menu Schedule

STATISTICAL ANALYSES

Verification of Treatment

Verification of Baseline Adjusted Readings

Verification of Corrected Baseline-Adjusted Readings

Verification of AUC calculations (ChromaMeter)

STATEMENT:

To the best of my knowledge, this report accurately represents the clinical conduct observed and data supplied for Quality Assurance review.

A handwritten signature in dark ink, appearing to read "Joe S. Henretty", is written over a horizontal line.

Joseph S. Henretty
Quality Assurance Specialist
Novum Pharmaceutical Research Services

Date:

03/26/02



CERTIFICATION OF GENERIC DRUG ENFORCEMENT ACT

Sponsor: Altana, Inc.
Drug: Lidex[®] E (fluocinonide) Cream 0.05 % and
Lidex[®] (fluocinonide) Cream 0.05 %
Study Title: A One Period, Randomized, Vasoconstrictor Assay Study To
Compare the Relative Vasoconstrictive Effects of Two Topical
Fluocinonide 0.05 % Creams
Study Number: 10228207
Protocol Number: 10228207 (Revision 1)

In Compliance with the requirements of the Generic Drug Enforcement Act of 1992, Novum Pharmaceutical Research Services (Novum) hereby certifies to Altana, Inc. that Novum did not and will not use in any manner the services of any person debarred under subsection (a) or (b) of Section 306 of the Generic Drug Enforcement Act of 1992 (21 U.S.C. S335a) (the "Act"). Novum and affiliated persons of Novum responsible for the development or submission of any application for the approval of a drug product have not had or been involved in any convictions as described in subsections (a) and (b) of Section 306 of the Act. This certification is made solely for the benefit of Altana, Inc. and may not be used by any other person or entity. Novum also certifies that we employ all applicable Good Clinical Practices standards.

A handwritten signature in cursive script, appearing to read "Marie R. Mayer", is written over a horizontal line.

Marie R. Mayer
Director, Quality Assurance
Novum Pharmaceutical Research Services

03/26/02
Date




CERTIFICATION OF FINANCIAL DISCLOSURE


Sponsor: Altana, Inc.
Drugs: Lidex[®] E (fluocinonide) Cream 0.05 % and
Lidex[®] (fluocinonide) Cream 0.05 %
Study Title: A One Period, Randomized, Vasoconstrictor Assay Study To
Compare the Relative Vasoconstrictive Effects of Two Topical
Fluocinonide 0.05 % Creams
Study Number: 10228207
Protocol Number: 10228207 (Revision 1)

In compliance with the requirements of 21 CFR Part 54, Financial Disclosure by Clinical Investigators, Novum Pharmaceutical Research Services (Novum) hereby certifies to Altana, Inc. that none of the clinical investigators listed on the FDA 1572 for this study, nor their spouse or dependent children have:

- Received any compensation that was dependent on the outcome of the study, nor will they receive any additional payments such as royalty payments based on product sales.
- Have any equity interest such as ownership, stock options, or publicly traded stock in Altana, Inc. whose total value exceeds \$50,000.
- Has any proprietary interests such as a patent, trademark, or licensing agreements in the product tested.
- Has received any other payment or equivalent from Altana, Inc., such as, on-going grant funding, consultant or honoraria payments, or clinical or laboratory equipment whose total value exceeds \$25,000.

This certification covers the duration of the study and a period of twelve months from the date of the final report. This certification is made solely for the benefit of Altana, Inc., and is applicable only to the study defined above. It may not be used by any other person or entity nor for any other study conducted by Novum.


Christopher H. Hendy, Ph.D.
President and CEO
Novum Pharmaceutical Research Services


Date

FLUOCINONIDE STUDY NO. 10228207

TABLE OF CONTENTS

VOLUME 1

Signature Page	
Quality Assurance Statement	
Certification of Generic Drug Enforcement Act	
Certification of Financial Disclosure	
Table of Contents	
Final Report Diskette	

Section 1: **SUMMARY**

I.	ABSTRACT	1
II.	OBJECTIVE	2
III.	INVESTIGATOR AND FACILITIES.....	2
	A. Investigator	
	B. Study Site	
IV.	INSTITUTIONAL REVIEW BOARD	2
V.	CLINICAL PROCEDURES.....	2
	A. Subject Selection	
	B. Dosing Procedures	
	C. Study Conduct	
VI.	DATA EVALUATION AND RESULTS.....	6
VII.	CONCLUSION.....	6
VIII.	SUMMARY TABLE AND GRAPH	6

Table

Mean ChromaMeter results for Lidex-E® (fluocinonide) Cream, 0.05% (Test) vs. Lidex® (fluocinonide) Cream, 0.05% (Reference) using Locke's Method for calculating confidence intervals.

Mean Graph

Results from Corrected, Adjusted ChromaMeter Readings – Mean Scores for Qualified Detectors (N=38)

FLUOCINONIDE STUDY NO. 10228207

TABLE OF CONTENTS

VOLUME 1 (continued)

Section 2: **PROCEDURES**

Protocol
Dosing Assignments (Randomization)
Form FDA 1572
Drug Receipt Correspondence
Investigational Drug Receipt Form
Investigational Drug Accountability Forms
Investigator Curriculum Vitae (including licenses)
NIIRB Submission and Approval Forms
NIIRB Membership List
Subject Consent Form

Section 3: **CLINICAL**

Table C1: Subject Characteristics
Table C2: Schedule of Treatments and Actual Application and Removal Times
Table C3: Summary of Adverse Events
Height and Weight Range Tables for Females
Activity Schedule
Meals and Menu Schedule

Section 4: **CHROMAMETER ASSESSMENTS**

- ChromaMeter Pre-dose Readings
- ChromaMeter Values as Read
- ChromaMeter Baseline-Adjusted Values
- ChromaMeter Adjusted ChromaMeter Scores Arranged by Treatment
- ChromaMeter Adjusted Scores Corrected by Untreated Sites
- ChromaMeter Negative Areas Under the Response Curve
- ChromaMeter Results – Qualification of Detectors
- ChromaMeter Results – Locke's Confidence Intervals

Section 5: **CHROMAMETER OPERATOR VALIDATIONS**

Summary Tables
Inter- and Intra-Site Precision of Chromameter A-Scale Readings

ChromaMeter Operators WSB, DMC, CLN and JAG (Study No. 10228207)
ChromaMeter Operators MLC and VSA (Dose Response Study No. 10228206)

FLUOCINONIDE STUDY NO. 10228207

TABLE OF CONTENTS

VOLUME 1 (continued)

Section 6: **MEDICAL**

Subject Case Report Forms (Subjects 01-46)

VOLUME 2

Section 6: **MEDICAL (cont.)**

Subject Case Report Forms (Subjects 47-60)

APPENDIX: Novum Study No. 10228206: “Dose Response of Lidex® Cream 0.05%”